Methyldopa Bristol Laboratories

Methyldopa, the active ingredient in Methyldopa Bristol Laboratories, is an Alpha-2 adrenergic agonist presented as an oral formulation for systemic use. It acts centrally to reduce sympathetic nervous system activity, providing a reliable option for lowering elevated blood pressure in adults and in certain pregnancy‑related hypertensive conditions.

GNH USA supplies Methyldopa Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets. Our distribution network adheres to Good Distribution Practice, enabling timely delivery and support for regulatory submissions.

Methyldopa is indicated for conditions involving elevated blood pressure and is commonly used in the following clinical settings.

Hypertension: controls high blood pressure in adults with essential hypertension. Pregnancy‑induced hypertension: provides safe blood pressure management during pregnancy. Gestational hypertension: helps maintain target blood pressure levels in pregnant women developing hypertension after 20 weeks.

Methyldopa may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Dry mouth

Serious or Rare Side Effects: - Liver dysfunction - Hemolytic anemia - Lupus‑like syndrome

When prescribing or dispensing Methyldopa, several safety considerations should be observed. - Monitor blood pressure regularly: adjust therapy based on target values. - Assess liver function periodically: methyldopa can affect hepatic enzymes. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Use caution in patients with cardiovascular disease: may exacerbate heart failure. - Check for hypersensitivity: discontinue if rash or angioedema occurs. - Store at ambient temperature: keep in original container, protect from moisture.

Methyldopa can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Clonidine: additive central alpha‑2 stimulation may cause excessive hypotension. - Other antihypertensives with strong hypotensive action: may lead to dangerously low blood pressure.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure‑lowering effect. - Beta‑blockers: combined effect on heart rate and blood pressure needs monitoring. - NSAIDs: may reduce antihypertensive efficacy.